Figure S1. Changes in the Prevalence of Selected CVD Risk Factors by Treatment Group
Shown in panels A-C is the unadjusted prevalence (%) at baseline and follow-up annual visits for participants in the immediate (I, solid line) and deferred (D, dashed line) ART groups for CVD (cardiovascular disease) risk factor, including hypertension (panel A), dyslipidemia (panel B), and current smoking (panel C). Presented within panels A-C are overall estimated differences in prevalence (with 95% confidence interval and p-value) over follow-up between the two groups (immediate minus deferred), adjusting for the baseline prevalence and visit from generalized estimating equations. Shown in panels D-E are the unadjusted mean changes from baseline at annual visits for participants in both ART groups for the following measures: body mass index (BMI, panel D) and glucose (panel E). Presented within panels D-E is the estimated mean difference (with 95% confidence interval and p-value) over follow-up between the two groups (immediate minus deferred), adjusting for the baseline value and visit from longitudinal mixed models. Figures are truncated at Month 48.
Appendix: The INSIGHT START (Strategic Timing of AntiRetroviral Treatment) Study Group
In addition to writing group, the following committee members contributed to the conduct of the START trial:
